# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sens...
GLP study marks a key milestone in Autonomix's path to achieve regulatory approvalsCompany remains on track to submit Inves...
New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a ...
On August 25, 2025, Autonomix Medical, Inc. (the "Company") entered into a purchase agreement, dated as of August 25, 2...
Global patent estate encompasses 80 issued patents and 40 pending patent applicationsStrengthens strategic position in a multi-...
Autonomix Medical (NASDAQ:AMIX) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1...